news releases

21 May 2015

FDA Grants Orphan-drug Designation for Echinomycin

OncoImmune, Inc. today was granted orphan-drug designation by the FDA for the use of echinomycin in the treatment of acute myeloid leukemia (AML).
Read more...
15 January 2015

OncoImmune Completes Phase I Clinical Study of CD24Fc

OncoImmune, Inc. today completed its Phase I clinical study of CD24Fc in healthy human subjects. This was a randomized, double-blind, placebo-controlled, single ascending dose study to assess the safety, tolerability, and pharmacokinetics of CD24Fc when…
Read more...
05 August 2013

OncoImmune Receives a $1 Million Grant from the National Institute of Health

OncoImmune, Inc. has received a two-year R01 grant for approximately $1,000,000 from the National Institute of Health to perform first-in-human study on safety and tolerability of CD24Fc in healthy volunteers.  This is a single dose…
Read more...
01 June 2013

OncoImmune Receives Grant from the State of Maryland

OncoImmune, Inc. announced that it has received a $250,000 grant from the State of Maryland Biotechnology Tax incentive program as a match of angel investment of $500,000.
Read more...

About Us

Based in Rockville, Maryland, OncoImmune is a
privately-held, clinical-stage biopharmaceutical
company that is actively engaged in the discovery
and development of biopharmaceuticals for the
treatment of cancer and autoimmune disease.

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.